Vimarsana
Biggest News Aggregation in the World

Action Date Anticipated News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Action Date Anticipated. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Action Date Anticipated Today - Breaking & Trending Today

ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results - Vimarsana News

ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results

Published: May 15, 2023

FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® for the Treatment of Allergic Reactions , Including Anaphylaxis New Drug and Marketing Authorization... | May 15, 2023

Source: marketscreener.com
Related Topics:
United StatesRichard LowenthalJustin ChakmaEric KarasAdvisory CommitteeDrug AdministrationPharmaceuticals IncAllergy Drug Advisory CommitteeEuropean Medicines AgencyDivision Of PulmonaryExchange Commission OnCommittee VotesFavorable Benefit Risk ProfileAllergic ReactionsMarketing Authorization ApplicationsUnder ReviewAction Date AnticipatedCash EquivalentsShort Term InvestmentsSupport Operating RunwayNext Three YearsPlanned CommercializationCommercial LaunchCommittee SupportsIncluding Anaphylaxis
ARS Pharmaceuticals Highlights Progress and Reports Fourth Quarter and Full Year 2022 Financial Results - Vimarsana News

ARS Pharmaceuticals Highlights Progress and Reports Fourth Quarter and Full Year 2022 Financial Results

Published: March 23, 2023

New Drug Application and Marketing Authorization Application for neffy® Currently Under Review with the FDA and EMA; FDA PDUFA Target Action Date Anticipated in Mid-2023 Strong Financial... | March 23, 2023

Source: marketscreener.com
Related Topics:
United StatesJustin ChakmaRichard LowenthalAmerican Academy Of AllergyEuropean Medicines AgencyPharmaceuticals IncExchange CommissionSilverback Therapeutics IncDrug AdministrationNew Drug ApplicationMarketing Authorization ApplicationCurrently Under ReviewAction Date AnticipatedFinancial PositionCash EquivalentsShort Term InvestmentsSupport Operating RunwayNext ThreeAllergic ReactionsIncluding AnaphylaxisUnder ReviewPrescription Drug User Fee ActData Supporting UseFull YearSilverback Therapeutics